

**Amendments to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original): A process for preparing the rosiglitazone maleate polymorph (Compound 1) substantially free of any other polymorphic forms, which comprises crystallizing rosiglitazone maleate in a solvent or mixture of solvents with a dielectric constant such that it provides Compound 1 substantially free of any other polymorphic forms.
2. (Original): A process for preparing the rosiglitazone maleate polymorph, Compound 1 substantially free of other polymorphs, which comprises crystallizing rosiglitazone maleate in a solvent with a dielectric constant of less than 21 or a mixture of solvents wherein at least one solvent has a dielectric constant of less than 21.
3. (Currently amended): A process as claimed in claim 1 ~~or claim 2~~ wherein the solvent is selected from anisole, isopropyl acetate, ethyl acetate, dichloroethane, methyl isobutyl ketone, n-butanol, propan-2-ol, toluene, dimethylcarbonate, or tetrahydrofuran or mixtures thereof.
4. (Currently amended): A process as claimed in ~~any of claims 1 to 3~~ claim 1 wherein the crystallization solvent is a mixture selected from ethyl acetate and IMS, toluene and IMS for dimethylcarbonate and IMS.
5. (Original): A process for preparing the rosiglitazone maleate polymorph (Compound 1) essentially free of any other polymorphic forms, which comprises crystallizing rosiglitazone maleate in a solvent or mixture of solvents with a dielectric constant such that it provides Compound 1 essentially free of any other polymorphic forms.

6. (Original): A process for preparing the Compound 1 essentially free of any other polymorphic forms of rosiglitazone maleate which comprises crystallizing rosiglitazone maleate from a solvent or mixture of solvents wherein the solvent or at least one of the solvents has a dielectric constant of less than 14.

7. (Original): A process as claimed in claim 5 for preparing the Compound 1 essentially free of any other polymorphic forms of rosiglitazone maleate which comprises crystallizing rosiglitazone maleate from a solvent or mixture of solvents with a dielectric constant of less than 14.

8. (Currently amended): A process as claimed in claim 6 ~~or claim 7~~ wherein the solvent has a dielectric constant of greater than 2.8 and less than 14.

9. (Currently amended): A process as claimed in ~~any of claims 5 to 8~~ claim 5 wherein the solvent is tetrahydrofuran.

10. (Currently amended): A process for preparing Compound 1 which comprises seeding a solution of rosiglitazone maleate in a suitable solvent with a dielectric constant >21, with Compound 1 essentially free of other polymorphic forms prepared according to the process as claimed in ~~any of claims 5 to 9~~ claim 5.

11. (Original): A process as claimed in claim 10 wherein the solvent is denatured ethanol.

12. (Cancelled).

13. (Original): A process for preparing the Compound 1 essentially free of any other polymorphic forms of rosiglitazone maleate which comprises crystallizing rosiglitazone maleate from a solvent or mixture of solvents selected from anisole, isopropyl acetate, ethyl acetate, dichloroethane, dimethyl carbonate, methyl isobutyl ketone, tetrahydrofuran or a mixture ethyl acetate and denatured ethanol (IMS).